Log in to save to my catalogue

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bulle...

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bulle...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e09e1cbdf70841de84cd0f2b971f8815

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

About this item

Full title

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

Publisher

England: BioMed Central Ltd

Journal title

Critical care (London, England), 2019-11, Vol.23 (1), p.383-383, Article 383

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined.
A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety...

Alternative Titles

Full title

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e09e1cbdf70841de84cd0f2b971f8815

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e09e1cbdf70841de84cd0f2b971f8815

Other Identifiers

ISSN

1364-8535

E-ISSN

1364-8535,1466-609X,1366-609X

DOI

10.1186/s13054-019-2627-y

How to access this item